High level of agreement in a fixed vs. live cell-based assay for antibodies to myelin oligodendrocyte glycoprotein in a real-world clinical laboratory setting

IntroductionAs recognition of myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease becomes more widespread, the importance of appropriately ordering and interpreting diagnostic testing for this antibody increases. Several assays are commercially available for MOG testing, and based...

Descripción completa

Detalles Bibliográficos

Autores principales:	Tammy L. Smith, Thomas R. Haven, Lauren M. Zuromski, Kyphuong Luong, Stacey L. Clardy, Lisa K. Peterson
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2023-07-01
Colección:	Frontiers in Neurology
Materias:	myelin oligodendrocyte glycoprotein (MOG) cell-based assay (CBA) MOG testing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) demyelinating disease fixed CBA
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1192644/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!